{"filing":{"accession_number":"0001437749-26-027356","cik":"0001742927","ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"rvph20260729_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/rvph20260729_8k.htm"},"events":[{"id":27322,"run_id":24887,"accession_number":"0001437749-26-027356","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Reviva disclosed Q2 2026 financial results (ended June 30, 2026) via press release, reporting a net loss of $2.4 million for the quarter and a cash position of $19.9 million as of quarter-end, along with recent clinical development milestones.","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28786,"accession_number":"0001437749-26-027356","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Reviva's financial results for Q2 2026 (ended June 30, 2026) via a press release attached as Exhibit 99.1. The filing includes condensed consolidated balance sheets and statements of operations showing a net loss of $2.4 million for the quarter and cash position of $19.9 million as of June 30, 2026. This is a standard quarterly earnings release disclosure material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:53:52.234302+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28787,"accession_number":"0001437749-26-027356","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 7.01 references Item 2.02 (Results of Operations and Financial Condition) and Exhibit 99.1 contains a press release titled \"Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights\" with detailed Q2 2026 financial statements showing net loss of $2.4 million and cash position of $19.9 million, along with clinical development milestones. This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:53:52.234302+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28786,"accession_number":"0001437749-26-027356","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Reviva's financial results for Q2 2026 (ended June 30, 2026) via a press release attached as Exhibit 99.1. The filing includes condensed consolidated balance sheets and statements of operations showing a net loss of $2.4 million for the quarter and cash position of $19.9 million as of June 30, 2026. This is a standard quarterly earnings release disclosure material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:53:52.234302+00:00","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","filing_date":"2026-08-12"},{"id":28787,"accession_number":"0001437749-26-027356","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 7.01 references Item 2.02 (Results of Operations and Financial Condition) and Exhibit 99.1 contains a press release titled \"Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights\" with detailed Q2 2026 financial statements showing net loss of $2.4 million and cash position of $19.9 million, along with clinical development milestones. This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:53:52.234302+00:00","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","filing_date":"2026-08-12"}]}